ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced ™Portal Offering Additional ™ Human Progenitor Cells Including Those for Diabetes Research BioTime, Inc. (NYSE MKT: BTX) and ...
BioTime has a broad scientific platform with multiple opportunities to enhance shareholder value. With the recent pullback in the stock price, valuations based on a sum-of-parts analysis appear ...
BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...
ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new ...
* BIOTIME INC - BIOTIME SUBSIDIARY, AGEX, TO RECEIVE UP TO $3.5 MILLION IN CASH * BIOTIME INC - AGEX RECEIVED APPROXIMATELY $3.2 MILLION UPON CLOSE OF ACQUISITION FOR ITS INTEREST IN ASCENDANCE * ...
The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker ...
(Reuters) - BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results